Nuwellis Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 154/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 11.00.In the medium term, the stock price is expected to trend down.Despite a good stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Nuwellis Inc's Score
Industry at a Glance
Industry Ranking
154 / 208
Overall Ranking
438 / 4582
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Hold
Current Rating
11.000
Target Price
+4890.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Nuwellis Inc Highlights
StrengthsRisks
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.74M.
Overvalued
The company’s latest PE is 0.01, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 13.52K shares, increasing 42.73% quarter-over-quarter.
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
Ticker SymbolNUWE
CompanyNuwellis Inc
CEOErb (John L)
Websitehttps://www.nuwellis.com/
FAQs
What is the current price of Nuwellis Inc (NUWE)?
The current price of Nuwellis Inc (NUWE) is 2.160.
What is the symbol of Nuwellis Inc?
The ticker symbol of Nuwellis Inc is NUWE.
What is the 52-week high of Nuwellis Inc?
The 52-week high of Nuwellis Inc is 70.140.
What is the 52-week low of Nuwellis Inc?
The 52-week low of Nuwellis Inc is 2.020.
What is the market capitalization of Nuwellis Inc?
The market capitalization of Nuwellis Inc is 2.95M.
What is the net income of Nuwellis Inc?
The net income of Nuwellis Inc is -10.62M.
Is Nuwellis Inc (NUWE) currently rated as Buy, Hold, or Sell?
According to analysts, Nuwellis Inc (NUWE) has an overall rating of Hold, with a price target of 11.000.
What is the Earnings Per Share (EPS TTM) of Nuwellis Inc (NUWE)?
The Earnings Per Share (EPS TTM) of Nuwellis Inc (NUWE) is 218.667.